IXICO plc Issue of Equity (8930C)
23 Junio 2021 - 9:32AM
UK Regulatory
TIDMIXI
RNS Number : 8930C
IXICO plc
23 June 2021
IXICO plc
("IXICO" or the "Company")
Issue of Equity
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , announces that it has made an
application to the London Stock Exchange for the admission to
trading on AIM of 181,852 new ordinary shares of 1p each ("New
Shares") to satisfy the exercise of options.
The New Shares are expected to be admitted to trading on AIM on
29 June 2021.
Total voting rights
Application has been made for admission to trading on AIM of
181,852 New Shares. Admission of the New Shares on AIM is expected
to become effective at 8.00 a.m. on 29 June 2021, following which
there will be in total 48,151,373 ordinary shares in the capital of
the Company in issue, each carrying equal voting rights.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in,
IXICO under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFLFFSRAIVFIL
(END) Dow Jones Newswires
June 23, 2021 10:32 ET (14:32 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024